Neurocrine Ends Work With Voyager on Gene Therapy on Extended Trial Hold

Neurocrine Ends Work With Voyager on Gene Therapy on Extended Trial Hold

285407

Neurocrine Ends Work With Voyager on Gene Therapy on Extended Trial Hold

Neurocrine Biosciences announced that it is stopping its work with Voyager Therapeutics to further develop VY-AADC (NBIb-1817) as a potential one-time gene therapy for Parkinson’s disease. The therapy, by Voyager and being advanced with Neurocrine’s support, is in a Phase 2 clinical trial (NCT03562494) that has been on hold since April 2020. The ending of this collaboration is effective on Aug. 2, but will not affect joint work in other disease programs, including that of the gene therapy…

You must be logged in to read/download the full post.